Trial Profile

A Phase II, Proof of Concept Study of PXS-5505A in Pancreatic Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PXS 5505A (Primary)
Indications Pancreatic cancer
Focus Proof of concept; Therapeutic Use

Most Recent Events

04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
05 Nov 2019 New trial record
24 Oct 2019 According to a Pharmaxis media release, the company plans to discuss with the FDA in coming months prior to filing an IND that supports entering this phase 2 study in 2H 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com